List of Sitavig drug patents

Sitavig is owned by Epi Hlth.

Sitavig contains Acyclovir.

Sitavig has a total of 3 drug patents out of which 0 drug patents have expired.

Sitavig was authorised for market use on 12 April, 2013.

Sitavig is available in tablet;buccal dosage forms.

Sitavig can be used as treatment of herpes labialis.

The generics of Sitavig are possible to be released after 16 June, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791127 EPI HLTH Mucosal bioadhesive slow release carrier for delivering active principles
Mar, 2027

(4 years from now)

US8747896 EPI HLTH Mucosal bioadhesive slow release carrier for delivering active principles
Jun, 2027

(4 years from now)

US8592434 EPI HLTH Mucoadhesive buccal tablets for the treatment of orofacial herpes
Jun, 2030

(7 years from now)

Drugs and Companies using ACYCLOVIR ingredient

Market Authorisation Date: 12 April, 2013

Treatment: Treatment of herpes labialis

Dosage: TABLET;BUCCAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic